Varenicline for smoking cessation

Author: Tonstad, Serena

Source: Expert Review of Neurotherapeutics, Volume 7, Number 2, February 2007 , pp. 121-127(7)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Varenicline is a selective αα₄ββ₂ nicotinic acetylcholine receptor partial agonist and the first non-nicotine-containing medication developed with the sole purpose of treating nicotine addiction. To date, four published clinical trials have demonstrated the efficacy and safety of varenicline for smoking cessation in healthy adults who were ready to make a quit attempt. One additional trial found that extended use of varenicline effectively reduced relapse to smoking. One trial to date published as a poster documented the 1-year safety of the drug. Varenicline was more efficacious than bupropion 24 weeks after randomization to a 12-week treatment course and 1 year after randomization in an identical trial. It has no contraindications except hypersensitivity and is well tolerated. This article reviews the available information on varenicline and discusses its clinical use.

Keywords: bupropion; nicotinic acetylcholine receptor partial agonist; nicotine replacement therapy; smoking cessation; varenicline

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14737175.7.2.121

Publication date: 2007-02-01

More about this publication?

Expert Review of Neurotherapeutics provides expert commentary on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer's and Parkinson's.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites